SEC filings and other documents

Raised FY26 EPS guidance after strong Q3 specialty and MSO-driven growth, with robust capital returns.

Guidance reaffirmed, growth to accelerate, $1B buybacks planned, and AI-driven efficiencies prioritized.

Raised EPS guidance and strong operating income growth offset revenue headwinds.

Expanded MSO ownership and robust specialty growth drive higher guidance and strategic focus.

Raised guidance and specialty investments drive strong growth and long-term confidence.

All proposals passed, with strong financial growth and major strategic investments announced.

Raised FY26 guidance after strong Q1, driven by specialty and MSO expansion.

Raised long-term growth guidance after key acquisitions and strong specialty segment performance.

Raised long-term growth guidance, MSO expansion, and balanced capital deployment drive outlook.

Specialty market leadership, MSO growth, and digital transformation drive strong financial outlook.

Raised long-term growth guidance after robust specialty-driven results and strategic investments.

Raised 2025 guidance, strong US specialty growth, and focus on digital and capital investments.

Raised growth guidance and strong MSO strategy drive robust performance and future investments.

Profit growth outpaces revenue as specialty, biosimilars, and RCA drive margin expansion.

Q3 delivered 21% operating income growth and raised guidance, driven by U.S. specialty strength.